This study is testing a new drug called DT120 for Major Depressive Disorder (MDD). DT120 works by affecting a specific receptor in the brain called serotonin 2A (5-HT2A). Researchers want to see if DT120 can improve symptoms of depression compared to a placebo (a substance with no active medicine). You might be able to join if you are 18 to 74 years old, have been diagnosed with MDD, and have been experiencing a depressive episode for at least 8 weeks but no more than 24 months. We will measure changes in your depression symptoms using a scale called the Montgomery-Åsberg Depression Rating Scale (MADRS) after 6 weeks to see if the treatment is successful. The current status of this study is unclear.

Study design

This is a Phase 3, double-blind (meaning neither you nor your doctor will know if you're getting DT120 or placebo), placebo-controlled study with about 165 participants. It includes an open-label extension where all participants receive DT120.

What's involved

You would participate in a 12-week randomized treatment period, followed by a 40-week extension phase where you might receive DT120.

Compensation

Not stated in the trial record.

Follow-up

Your depression symptoms will be measured at Week 6, and you will be monitored and evaluated for potential retreatment with DT120 during the 40-week extension phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.